We are advancing wound care using our 30Technology™ to improve healing rates, reduce healing times and address infection.
Our lead product is a revolutionary wound therapy which prevents infection, accelerates healing, and uniquely leverages the anti-microbial and healing properties of the NO pathway whilst simultaneously providing a moist wound environment.
The product has peer-reviewed safety and efficacy data in a multi-centre randomised clinical study in diabetic foot ulcers. The product significantly improves healing whilst reducing serious adverse outcomes, such as diabetes-related amputations.
There are significant unmet clinical needs in improving diabetic foot ulcer (DFU) care. Over one in 16 people in the UK have diabetes, with an estimated increase to one in ten by 2030. DFUs precede more than 80% of amputations in people with diabetes, the most common cause of lower limb amputation. There are over 135 diabetes related amputations a week in the UK, a major cause of morbidity and an enormous drain on health-care resources with an annual NHS spend of over £1 billion
The increasing rate of antimicrobial resistance threatens the effectiveness of antibiotics now and in the future, posing a serious issue for public health. In the United States alone over 2 million people suffer from antibiotic resistant infections costing $20 billion a year. Across Europe, approximately 25,000 people die each year due to antimicrobial resistant hospital infections. One in three hospital patients are on antibiotics at any one time in England.
There is an urgent need to develop new treatments for non-healing wounds to reduce the burden of care in an efficient and cost-effective way. We are expanding the clinical evidence of the product in chronic and acute wound care and our lead product is being readied for Regulatory Approval.
There are over 200 million surgical incisions per year, with surgical site infection well recognised as a serious and expensive complication in up to 5% of surgical procedures.
Pressure ulcers are a commonly encountered condition in both acutely hospitalised and long-term institutionalised patients. They are estimated to occur in approximately 9% of hospitalised patients, usually during the first 2 weeks of hospitalisation and in up to 28% of long-term care residents.
Combined with its potent anti-microbial activity, there is a real opportunity to make a significant different in the acute wound care setting.
VENOUS LEG ULCERS
Venous leg ulcers (VLUs) are open lesions between the knee and ankle joint that occur in the presence of venous disease. Approximately 2% of the population may experience VLUs in their lifetime – 60% of these ulcers take longer than 2 years to heal.
30 TECHNOLOGY is developing and defining new models of care to treat many serious medical conditions by enhancing the body’s healing and defence mechanisms.
30 TECHNOLOGY Therapeutic Nitric Oxide